ABV is a combination of intravenous anti-cancer drugs consisting of doxorubicin (Caelyx / Myocet), bleomycin (Bleo-Kyowa) and vincristine (Oncovin). ABVD is ABV with the addition of dacarbazine (DTIC-Dome). It is being studied as a treatment for Kaposi's sarcoma, non-Hodgkin's lymphoma and lymphoma.

The side-effects of this regimen may be reduced by the use of the growth factors granulocyte macrophage colony stimulating factor (GM-CSF) or granulocyte colony stimulating factor (G-CSF).